Aagami, Inc. Market Research Report

Company Overview

Name: Aagami, Inc.

Mission: No information is available.

Founded: No information is available.

Founder(s): No information is available.

Key People:

Dinesh Jain, BE, MBA - Founder and CEO

Michael S Rosen - Partner Consultant

Godwyn Francis - Vice President

Nancy Chew - Regulatory Advisor

Shridhar Andurkar, PhD - Scientific Advisor

Dr. Aman Ahuja - Medical Advisor

Headquarters: 2020 Calamos Court, Suite 200, Naperville, IL 60563, USA

Number of Employees: No information is available.

Revenue: No specific revenue figure is provided, but 2024 was the highest annual revenue in strategic consulting.

What the Company is Known For:

Business development support, strategic consulting, technology licensing, and market intelligence for global life sciences sectors.

Experience in overcoming business and socio-cultural differences, extensive 'C' level networking, and global deal-making skills with partners' combined experience of over 250 years.

Facilitated over 500 MM USD in cross-border deals and investments.

Products

Aagami does not offer proprietary products but provides services. Therefore, specific product descriptions are not applicable.

Recent Developments

2024 Updates and Developments

Contract Expansions: Received extensions and expansions from multiple clients, including:

A US client involved in JV/Acquisition/Investment initiatives for a Smart Drug.

New nutraceuticals portfolio developed for U.S. and global markets.

New Product Launches: Involvement with various dietary supplements entering the market:

Greenselenium®: Addresses chronic inflammatory conditions and has pharmaceutical potential.

SlimTrym®: Aims at obesity prevention and treatment.

Turmericimmune™: Enhances tissue repair and immunity.

FB3® Fusion: Targets healthy weight management.

Kannan™: Addresses stress, mood, anxiety, and cognition.

Adaptrin®: Supports cardiovascular and immune systems.

Serenity-151™: Improves anti-stress and intellectual performance.

Vigor-149: Supports hormonal balance and libidos in stress-affected individuals.

Patented Technology: Client's proprietary Strip Melts® Technology for OTF delivery system, especially for individuals with difficulty swallowing pills.

Strategic Partnerships and Business Growth

Conference Participation: Attended multiple industry-leading conferences and partnership meetings, including:

JP Morgan Healthcare Week

Biotech Showcase

BIO International

Global Pharma Partnering

Client Engagement: Over 160 strategic one-on-one meetings conducted at various events to enhance business opportunities and partnerships.

New Client Acquisitions: Added several new clients, including notable wins from Japan in Oligonucleotide and Peptide APIs manufacturing.

Investment Highlights

Investment Opportunities: Seeking up to US$25 million in advanced seed funding (culminating in Series A) for strategic investors with stakes in Pharma and Nutra divisions.

Involvement with Large Pharma: Revenue models and terms under discussion with a large pharma company for a Korean client.

Achievements

Awards and Recognition: Involvement of distinguished inventors and scientists with multiple patents and scientific publications enhancing the company's credibility in life sciences.

Future Plans

Intent to continue attending major partnering events in 2025 and leverage these opportunities for strategic growth and partnerships.

Contact Information

Address: 2020 Calamos Court, Suite 200, Naperville, IL 60563, USA

Phone: +1-630-364-1837

Email: dinesh@aagami.com

This report encapsulates the current data regarding Aagami, Inc.’s business development, strategic consulting services, and presence in the global market. This may provide potential investors, partners, and clients with an insightful understanding of the company’s operations and market position.